Core Scientific to be Acquired by CoreWeave; Restates Q2 2025 Financials, Cites Material Weakness

summarizeSummary

Core Scientific announced its acquisition by CoreWeave in an all-stock transaction while simultaneously restating its Q2 2025 financials due to a $127.3 million overstatement of assets and disclosing a material weakness in internal controls.

check_boxKey Events

• Merger Agreement Announced

  Core Scientific entered into an Agreement and Plan of Merger with CoreWeave, Inc. on July 7, 2025, under which CoreWeave will acquire Core Scientific in an all-stock transaction. Each outstanding share of Core Scientific common stock will be converted into 0.1235 shares of CoreWeave Class A common stock.

• Financial Restatement for Q2 2025

  The company restated its Quarterly Report on Form 10-Q for the period ended June 30, 2025, and other prior periods, correcting a $127.3 million overstatement of property, plant, and equipment and a $4.4 million understatement of selling, general and administrative expense for the six months ended June 30, 2025. Previously issued financials should no longer be relied upon.

• Material Weakness in Internal Controls

  Management identified a material weakness in internal control over financial reporting as of December 31, 2024, which continued through June 30, 2025, related to accounting for assets committed to demolition during facility conversions. Disclosure controls and procedures were deemed not effective.

auto_awesomeAnalysis

This filing reveals two major, but contrasting, developments. The announcement of an all-stock acquisition by CoreWeave is a transformative event for Core Scientific, offering shareholders a clear path forward and potentially a premium. However, this positive news is coupled with a significant restatement of Q2 2025 financials and prior periods, correcting a $127.3 million overstatement of assets and a $4.4 million understatement of selling, general and administrative expenses for the six months ended June 30, 2025. The disclosure of a material weakness in internal controls further highlights past financial reporting issues. Investors will weigh the long-term benefits of the merger against the immediate concerns regarding financial reliability and internal control deficiencies. The company's plan to remediate the material weakness is crucial for investor confidence moving forward, especially as the merger progresses.